AMY HALL: Open Payments
NPI 1104402379 · LIVONIA, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,029 in 88 payments from 12 companies in 2025. Trend: 2023 $316 · 2024 $1,192 · 2025 $2,029
Food & beverage: $2,029
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $437 |
| Alkermes, Inc. | 16 | $405 |
| Vanda Pharmaceuticals Inc. | 11 | $316 |
| Teva Pharmaceuticals USA, Inc. | 9 | $291 |
| E.R. Squibb & Sons, L.L.C. | 12 | $147 |
| Otsuka America Pharmaceutical, Inc. | 5 | $113 |
| Neurocrine BioSciences, Inc. | 5 | $106 |
| Supernus Pharmaceuticals, Inc. | 5 | $91 |
| Lundbeck LLC | 4 | $64 |
| Almatica Pharma LLC | 1 | $29 |
Products named: VRAYLAR, ARISTADA, FANAPT, AUSTEDO XR, COBENFY, INGREZZA, Qelbree, REXULTI.
Industry payments across MI — which companies pay providers there.
